A61K51/1021 - CPC Classification Index

ClassID:

21587 ⎘

A61K51/1021 - CPC Classification

Classification description:

Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins; Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons

Recent Application in this class:

20250345438

2025-11-13

PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY

20250152760

2025-05-15

RADIOACTIVE COMPLEX OF ANTI-VEGF ANTIBODY, AND RADIOPHARMACEUTICAL

20240368264

2024-11-07

Anti-TSLP nanobodies and their applications

20240342322

2024-10-17

Netrin-1 detection, companion test and therapy based on radiations

20240325575

2024-10-03

LABELING OF ANTIBODIES

20240307562

2024-09-19

ANTI-oxMIF RADIOIMMUNOCONJUGATE

20240277876

2024-08-22

PET IMAGING TRACERS

20230381348

2023-11-30

BIFUNCTIONAL MACROCYCLIC CHELATE, CONJUGATE, METAL COMPLEX AND USE THEREOF

20230338589

2023-10-26

IN VIVO IMMUNOIMAGING OF INTERFERON-GAMMA

#10

20220387314

2022-12-08

ALBUMIN-PD-1 PACLITAXEL NANOPARTICLE COMPLEX COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

#11

20220372125

2022-11-24

Antigen Specific Binding Domains and Antibody Molecules

#12

20220370622

2022-11-24

Pharmaceutical compositions and related methods of delivery

#13

20220370621

2022-11-24

Pharmaceutical compositions and related methods of delivery

#14

20220287658

2022-09-15

IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12

#15

20220202967

2022-06-30

COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES

#16

20210322583

2021-10-21

RADIO-PHARMACEUTICAL COMPLEXES

#17

20210238270

2021-08-05

COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION

#18

20210095014

2021-04-01

Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof

#19

20210061919

2021-03-04

STABLE IgG4 ANTIBODIES

#20

20200397906

2020-12-24

Pharmaceutical compositions and related methods of delivery

#21

20200206371

2020-07-02

In vivo immunoimaging of interferon-gamma

#22

20200129647

2020-04-30

Methods for determining biodistribution of intravitreal administered medicaments

#23

20200085981

2020-03-19

Tumor targeted radionuclide therapy and molecular imaging of HER2+ cancers and other neoplasms

#24

20200062837

2020-02-27

ANTI-NGF COMPOSITIONS AND USE THEREOF

#25

20190276526

2019-09-12

COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION

#26

20190256588

2019-08-22

Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody

#27

20190169281

2019-06-06

ANGPTL8-binding agents and methods of use thereof

#28

20190038758

2019-02-07

PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY

#29

20180312581

2018-11-01

Method For Making Heteromultimeric Molecules

#30

20180280551

2018-10-04

Labeling of antibodies

#31

20170369568

2017-12-28

INTERFERON ALPHA ANTIBODIES AND THEIR USES

#32

20170340759

2017-11-30

RADIO-PHARMACEUTICAL COMPLEXES

#33

20170327568

2017-11-16

Anti-NGF compositions and use thereof

#34

20170182187

2017-06-29

Lyophilized compositions comprising albumin-rankl or albumin-GD2 paclitaxel nanoparticle complexes

#35

20170182186

2017-06-29

Methods of using albumin-antibody nanoparticle complex compositions for treating cancer

#36

20170182185

2017-06-29

Methods of using albumin-CD20 paclitaxel nanoparticle complex compositions for treating cancer

#37

20170182184

2017-06-29

Lyophilized compositions comprising albumin-antibody paclitaxel nanoparticle complexes

#38

20170182183

2017-06-29

Albumin-PD-1 paclitaxel nanoparticle complex compositions and methods of making and using the same

#39

20170182180

2017-06-29

Lyophilized compositions comprosing albumin-EGFR paclitaxel nanoparticle complexes

#40

20170182175

2017-06-29

Albumin-CTLA-4 paclitaxel nanopartilce complex compositions and methods of making and using the same

#41

20170182174

2017-06-29

Methods of making lyophilized compositions comprising albumin-VEGF paclitaxel nanoparticle complexes

#42

20170100492

2017-04-13

Carrier-antibody compositions and methods of making and using the same

#43

20170088635

2017-03-30

Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use

#44

20170071897

2017-03-16

Carrier-antibody compositions and methods of making and using the same

#45

20170029521

2017-02-02

Stable IgG4 antibodies

#46

20170021034

2017-01-26

Carrier-antibody compositions and methods of making and using the same

#47

20170021032

2017-01-26

Carrier-antibody compositions and methods of making and using the same

#48

20160339118

2016-11-24

Carrier-antibody compositions and methods of making and using the same

#49

20160338961

2016-11-24

Carrier-antibody compositions and methods of making and using the same

#50

20160326240

2016-11-10

Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof

#51

20160280774

2016-09-29

Method for making heteromultimeric molecules

#52

20160272706

2016-09-22

IL-13 BINDING PROTEINS AND USES THEREOF

#53

20160272703

2016-09-22

TNF-ALPHA BINDING PROTEINS

#54

20160207991

2016-07-21

Therapeutic Antibody

#55

20160184453

2016-06-30

Carrier-antibody compositions and methods of making and using the same

#56

20160184452

2016-06-30

Carrier-antibody compositions and methods of making and using the same

#57

20160184229

2016-06-30

Carrier-antibody compositions and methods of making and using the same

#58

20160158159

2016-06-09

Pharmaceutical compositions and related methods of delivery

#59

20160095942

2016-04-07

Carrier-antibody compositions and methods of making and using the same

#60

20150337035

2015-11-26

Antibodies to TNF α and use thereof

#61

20150147322

2015-05-28

Compositions and methods for targeting type 1 interferon producing cells

#62

20150147271

2015-05-28

Treatment of acute myeloid leukemia and myelodysplastic syndromes

#63

20150056133

2015-02-26

CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

#64

20150031631

2015-01-29

Pharmaceutical compositions and related methods of delivery

#65

20140302055

2014-10-09

Antibodies Directed to Angiopoietin-like Protein 4 and Uses Thereof

#66

20140234208

2014-08-21

Dual variable domain immunoglobulins and uses thereof

#67

20140219912

2014-08-07

DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

#68

20140199328

2014-07-17

Methods for preparing interferon alpha antibodies

#69

20140086829

2014-03-27

Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions

#70

20130295006

2013-11-07

Pharmacokinetic determination of intravitreal agents

#71

20120275996

2012-11-01

IL-1 Binding Proteins

#72

20120230911

2012-09-13

TNF-α binding proteins

#73

20120164067

2012-06-28

Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75

#74